Lite Strategy Pivots to Crypto with $100M Litecoin Treasury

Ticker: LITS · Form: 10-K · Filed: Sep 26, 2025 · CIK: 1262104

Lite Strategy, INC. 10-K Filing Summary
FieldDetail
CompanyLite Strategy, INC. (LITS)
Form Type10-K
Filed DateSep 26, 2025
Risk Levelhigh
Pages15
Reading Time18 min
Key Dollar Amounts$0.00000002, $100.0 million, $3.42, $3.4199, $4.10
Sentimentbearish

Sentiment: bearish

Topics: Cryptocurrency, Strategic Pivot, Biotech, PIPE, Litecoin, Risk Factors, Capital Allocation

Related Tickers: LTC

TL;DR

**LITS just went full crypto, ditching cancer drugs for Litecoin; it's a moonshot or bust, so buckle up or bail out.**

AI Summary

Lite Strategy, Inc. (LITS) underwent a significant strategic shift in fiscal year 2025, transitioning from a pharmaceutical company to one focused on a Litecoin Treasury Strategy. On September 10, 2025, MEI Pharma, Inc. officially changed its name to Lite Strategy, Inc. and its ticker to LITS. The company discontinued clinical development of its lead drug candidate, voruciclib, as of July 22, 2024, and reduced its workforce starting August 1, 2024. In July 2025, LITS closed a $100.0 million Private Investment in Public Equity (PIPE), issuing 23,216,898 shares of common stock at $3.42 per share and pre-funded warrants for 6,022,869 shares at $3.4199 per warrant. The net proceeds from this PIPE were fully deployed on August 5, 2025, into a Litecoin Treasury Strategy, acquiring Litecoin (LTC) tokens. The company also plans to assess pre-clinical activities for its drug pipeline and potentially commence Litecoin mining activities. The aggregate market value of common equity held by non-affiliates was approximately $12.0 million as of December 31, 2024.

Why It Matters

Lite Strategy's dramatic pivot from oncology drug development to a Litecoin Treasury Strategy represents a high-risk, high-reward gamble for investors. This move signals a complete reorientation of the company's business model, abandoning years of pharmaceutical R&D for an unproven venture into digital assets and potentially crypto mining. For employees, this shift has already resulted in a reduction-in-force starting August 1, 2024, and creates significant uncertainty regarding future roles. Customers, previously patients relying on potential cancer therapies, are directly impacted by the discontinuation of clinical trials for voruciclib. The broader market will watch LITS as a bellwether for other small-cap companies considering similar radical shifts into the volatile cryptocurrency space, potentially setting a precedent for capital structure innovation or cautionary tales.

Risk Assessment

Risk Level: high — The risk level is high due to the complete abandonment of its established pharmaceutical business for a highly volatile and speculative Litecoin Treasury Strategy. The company deployed the full net proceeds of a $100.0 million PIPE into Litecoin tokens on August 5, 2025, exposing its entire capital base to cryptocurrency market fluctuations. Furthermore, the company is considering commencing Litecoin mining activities, which introduces operational and energy-related risks in an entirely new industry.

Analyst Insight

Investors should approach LITS with extreme caution, recognizing the company's complete business model transformation into a speculative cryptocurrency play. This is a high-risk investment suitable only for those with a strong appetite for volatility and belief in the long-term value of Litecoin, as the company's future is now directly tied to LTC's performance.

Financial Highlights

debt To Equity
N/A
revenue
$0
operating Margin
N/A
total Assets
N/A
total Debt
N/A
net Income
N/A
eps
N/A
gross Margin
N/A
cash Position
N/A
revenue Growth
N/A

Key Numbers

Key Players & Entities

FAQ

What is Lite Strategy, Inc.'s new business focus?

Lite Strategy, Inc. (LITS) has shifted its primary business focus from developing cancer therapies to implementing a Litecoin Treasury Strategy, which involves acquiring Litecoin (LTC) tokens and potentially commencing Litecoin mining activities. This strategic pivot was announced on August 5, 2025, following a $100.0 million PIPE.

How much capital did Lite Strategy raise and how was it used?

Lite Strategy, Inc. (LITS) closed a $100.0 million Private Investment in Public Equity (PIPE) in July 2025. The net proceeds from this PIPE were fully deployed on August 5, 2025, into a Litecoin Treasury Strategy, primarily through the acquisition of Litecoin (LTC) tokens.

What happened to Lite Strategy's drug development programs?

Lite Strategy, Inc. (LITS) discontinued the clinical development of its lead drug candidate, voruciclib, as of July 22, 2024. While certain nonclinical activities related to its drug candidate assets continue, the company is assessing pre-clinical development in potentially non-oncology disease indications.

Who are the key executives at Lite Strategy after the strategic shift?

Following the strategic shift, Justin J. File, the former Chief Financial Officer, assumed the position of Acting Chief Executive Officer. Frederick W. Driscoll was appointed Chairperson of the Board. David M. Urso and Richard Ghalie, M.D., stepped down as President and CEO, and Chief Medical Officer, respectively, on August 1, 2024.

What are the risks associated with Lite Strategy's new Litecoin Treasury Strategy?

The new Litecoin Treasury Strategy exposes Lite Strategy, Inc. (LITS) to significant risks, primarily the high volatility of cryptocurrency markets. The company has deployed its entire $100.0 million PIPE proceeds into Litecoin, making its financial performance directly dependent on LTC's price fluctuations. Additionally, potential Litecoin mining activities introduce new operational and energy-related risks.

What was the aggregate market value of Lite Strategy's common equity held by non-affiliates?

As of December 31, 2024, the aggregate market value of the voting and non-voting common equity held by non-affiliates of Lite Strategy, Inc. (LITS) was approximately $12.0 million, based on the closing price per share of its Common Stock on the Nasdaq Capital Market.

Did Lite Strategy pay any dividends recently?

Yes, Lite Strategy, Inc. (LITS) paid a cash dividend of $1.75 per share of common stock on December 6, 2023. This dividend, totaling $11.7 million, was a capital return to stockholders as part of a cooperation agreement with Anson Funds Management LP and Cable Car Capital LLC.

What is voruciclib and its status?

Voruciclib is an oral cyclin-dependent kinase 9 (CDK9) inhibitor that Lite Strategy, Inc. (LITS) was developing as a cancer therapy. All clinical trial efforts for voruciclib were ceased as of July 22, 2024, though the company is currently assessing its pre-clinical development program for potentially non-oncology disease indications.

What was the outcome of the proposed merger with Infinity Pharmaceuticals, Inc.?

The proposed merger between Lite Strategy, Inc. (LITS) and Infinity Pharmaceuticals, Inc. did not obtain the necessary approval from Lite Strategy's stockholders at a special meeting held on July 23, 2023. Consequently, Lite Strategy sent Infinity a notice terminating the Merger Agreement on the same day.

How many shares of common stock are outstanding for Lite Strategy, Inc.?

As of September 23, 2025, there were 35,655,155 shares of Lite Strategy, Inc.'s common stock, par value $0.00000002 per share, outstanding.

Risk Factors

Industry Context

Lite Strategy, Inc. is operating in a nascent and highly volatile digital asset management industry. The competitive landscape includes various cryptocurrency funds, decentralized finance (DeFi) protocols, and other corporate treasuries exploring digital asset holdings. Key industry trends involve increasing institutional adoption of cryptocurrencies, evolving regulatory frameworks, and the development of new blockchain technologies.

Regulatory Implications

The company's shift to a Litecoin Treasury Strategy introduces significant regulatory uncertainty. Evolving global regulations around digital assets, cryptocurrency exchanges, and treasury management of digital currencies could impact its operations, compliance costs, and the valuation of its assets.

What Investors Should Do

  1. Monitor Litecoin (LTC) price volatility and market trends.
  2. Evaluate the company's risk management framework for digital assets.
  3. Assess the evolving regulatory landscape for digital assets.
  4. Analyze the company's ability to execute its Litecoin Treasury and potential mining strategies.

Key Dates

Glossary

Litecoin Treasury Strategy
A strategy where a company holds and manages a significant portion of its assets in the form of Litecoin (LTC) cryptocurrency. (This is the core new business strategy of Lite Strategy, Inc., replacing its previous pharmaceutical focus.)
PIPE
Private Investment in Public Equity. A transaction where a public company sells its securities directly to a private investor or group of investors at a negotiated price. (The company raised $100.0 million through a PIPE offering, which was then deployed into its Litecoin Treasury Strategy.)
Voruciclib
An oral cyclin-dependent kinase 9 (CDK9) inhibitor that was previously Lite Strategy, Inc.'s lead drug candidate. (The discontinuation of its development signifies the company's pivot away from its pharmaceutical pipeline.)
Pre-funded Warrants
A type of warrant that allows the holder to purchase shares at a nominal exercise price, often used in PIPE transactions to provide immediate equity ownership. (Issued as part of the PIPE offering, indicating a structure to provide immediate equity to investors.)
Asset-based Fee
A fee paid to a service provider that is calculated based on the value of assets managed or held. (Indicates a payment structure for services rendered, such as to GSR, tied to the company's asset holdings.)

Year-Over-Year Comparison

This filing represents a radical departure from the previous year's operations. Lite Strategy, Inc. (formerly MEI Pharma) has transitioned from a pharmaceutical development company to a cryptocurrency-focused entity. Key metrics such as revenue, net income, and margins from pharmaceutical operations are no longer relevant. The company's financial position is now defined by its holdings of Litecoin and the capital raised through a recent PIPE offering, rather than drug pipeline progress or sales.

Filing Stats: 4,469 words · 18 min read · ~15 pages · Grade level 16.2 · Accepted 2025-09-26 16:00:57

Key Financial Figures

Filing Documents

Business

Business 5 Item 1A:

Risk Factors

Risk Factors 19 Item 1B: Unresolved Staff Comments 29 Item 1C: Cybersecurity 29 Item 2:

Properties

Properties 30 Item 3:

Legal Proceedings

Legal Proceedings 30 Item 4: Mine Safety Disclosures 30 PART II Item 5: Market for the Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 30 Item 6: [Reserved] 31 Item 7:

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 31 Item 7a:

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 37 Item 8: Consolidated Financial Statements and Supplementary Data 38 Item 9: Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 64 Item 9A:

Controls and Procedures

Controls and Procedures 64 Item 9B: Other Information 64 Item 9C: Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 65 PART III Item 10: Directors, Executive Officers and Corporate Governance 66 Item 11:

Executive Compensation

Executive Compensation 72 Item 12:

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 84 Item 13: Certain Relationships and Related Transactions and Director Independence 85 Item 14: Principal Accountant Fees and Services 85 PART IV Item 15: Exhibits, Financial Statement Schedules 87 Item 16: Form 10-K Summary 89 Table of Contents

Forward-Looking Statements

Forward-Looking Statements This Annual Report on Form 10-K (Annual Report) includes forward-looking statements, which involve a number of risks and uncertainties. These forward-looking statements can generally be identified as such because the context of the statement will include words such as "may," "will," "intend," "plan," "believe," "anticipate," "expect," "estimate," "predict," "potential," "continue," "likely," or "opportunity," the negative of these words or other similar words. Similarly, statements that describe our future plans, strategies, intentions, expectations, objectives, goals or prospects and other statements that are not historical facts are also forward-looking statements. Discussions containing these forward-looking statements may be found, among other places, in "Business" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in this Annual Report. For such statements, we claim the protection of the Private Securities Litigation Reform Act of 1995. Readers of this Annual Report are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the time this Annual Report was filed with the Securities and Exchange Commission, or SEC. These forward-looking statements are based largely on our expectations and projections about future events and future trends affecting our business and are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. These risks and uncertainties include, without limitation, those discussed in "Risk Factors" and in "Management's Discussion and Analysis of Financial Condition and Results of Operations" of this Annual Report. Other sections of this report and our other filings with the SEC may include additional factors which could adversely impact our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environme

Business

Item 1. Business Overview On September 10, 2025, MEI Pharma, Inc. changed its name to Lite Strategy, Inc. and its ticker symbol to LITS. We are a pharmaceutical company that has been developing novel and differentiated cancer therapies. We built our pipeline by acquiring promising cancer agents and creating value in programs through clinical development, strategic partnerships and out-licensing or commercialization, as appropriate. Our approach to oncology drug development has been to evaluate our drug candidates in combinations with standard-of-care therapies to overcome known resistance mechanisms and address clear medical needs to provide improved patient benefit. Our drug candidate pipeline includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor, which is a pre-clinical candidate . In August 2025, as described below, we implemented a Litecoin Treasury Strategy with the net proceeds from the PIPE (as defined below). Strategic Alternatives On July 22, 2024, we announced that our Board of Directors (Board) had determined unanimously to begin the evaluation of our strategic alternatives, including potential transactions as well as an orderly wind down of operations, if appropriate, to maximize the value of our assets for our stockholders. We commenced a reduction-in-force beginning August 1, 2024, that continued in stages as our operational and strategic direction evolved. In connection with this evaluation, we discontinued the clinical development of voruciclib, while certain nonclinical activities related to our drug candidate assets continued to be conducted by us. As part of the review of strategic alternatives, we considered options such as out-licensing opportunities for or the sale of our existing programs and merger and acquisition opportunities, as well as other potential opportunities. Consistent with our intention to preserve cash, David M. Urso, our President and Chief

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing